PBYI
PBYI clinical trials: PUMA BIOTECHNOLOGY, INC.
Every trial on ClinicalTrials.gov where PUMA BIOTECHNOLOGY, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 59
- Trials linked
- 38
- As lead sponsor
- 21
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
PBYI on the catalyst calendar · PBYI registry changes
- Primary completion Mar 31, 2028Sponsor estimatePhase 2NCT07465757A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)Puma Biotechnology, Inc. · Small Cell Lung Cancer ( SCLC )RecruitingPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2027Sponsor estimatePhase 2NCT06369285A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerPuma Biotechnology, Inc. · Hormone Receptor Positive HER-2 Negative Breast CancerRecruitingPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 30, 2027Sponsor estimatePhase 2NCT06095505A Study of Alisertib in Patients With Extensive Stage Small Cell Lung CancerPuma Biotechnology, Inc. · Small Cell Lung CancerRecruitingPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2, 2023ActualPhase 2NCT01953926Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsPuma Biotechnology, Inc. · Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsTerminatedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 28, 2021ActualPhase 2NCT04366713A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With NeratinibPuma Biotechnology, Inc. · HER2 Amplified Breast CancerCompletedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 22, 2021ActualPhase 2NCT02400476An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With...Puma Biotechnology, Inc. · Early Stage HER2+ Breast CancerCompletedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 28, 2018ActualPhase 3NCT01808573A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have...Puma Biotechnology, Inc. · HER2+ Metastatic Breast Cancer (MBC)CompletedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 21, 2021ActualNo phase registeredNCT03786107HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of NeratinibPuma Biotechnology, Inc. · Hormone Receptor-Positive, HER2-Negative Metastatic Breast CancerTerminatedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 21, 2014ActualPhase 3NCT00878709Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast CancerPuma Biotechnology, Inc. · Breast CancerCompletedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2011ActualPhase 1NCT01128842A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid TumorPuma Biotechnology, Inc. · Advanced Malignant Solid TumorsCompletedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2016ActualPhase 1/Phase 2NCT01111825Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast CancerPuma Biotechnology, Inc. · Breast CancerCompletedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2011ActualPhase 1NCT00838539Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid TumorsPuma Biotechnology, Inc. · NeoplasmsCompletedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2007ActualPhase 1NCT00146172Study Evaluating HKI-272 in TumorsPuma Biotechnology, Inc. · Breast NeoplasmsCompletedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2009ActualPhase 1NCT00397046A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid TumorsPuma Biotechnology, Inc. · TumorsCompletedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2008ActualPhase 2NCT00300781Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast CancerPuma Biotechnology, Inc. · Breast NeoplasmsCompletedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2010ActualPhase 1/Phase 2NCT00741260Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast CancerPuma Biotechnology, Inc. · Breast CancerCompletedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2013ActualPhase 2NCT00915018Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast CancerPuma Biotechnology, Inc. · Breast CancerCompletedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2011ActualPhase 2NCT00777101Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast CancerPuma Biotechnology, Inc. · Advanced Breast CancerCompletedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2009ActualPhase 1/Phase 2NCT00706030Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast CancerPuma Biotechnology, Inc. · Breast CancerCompletedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2011ActualPhase 1/Phase 2NCT00445458A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast CancerPuma Biotechnology, Inc. · Advanced Breast CancerCompletedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2009ActualPhase 1/Phase 2NCT00398567A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast CancerPuma Biotechnology, Inc. · Advanced Breast CancerCompletedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 20, 2016ActualPhase 2NCT01827267Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung CancerPuma Biotechnology, Inc. · HER2-mutant Non-Small Cell Lung CancerCompletedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2010ActualPhase 1NCT00958724Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid TumorsPuma Biotechnology, Inc. · Advanced Malignant Solid TumorsCompletedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2011ActualPhase 1NCT00768469Study Evaluating Safety And Tolerability, Solid TumorPuma Biotechnology, Inc. · Advanced Malignant Solid TumorsCompletedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2009ActualPhase 2NCT00266877Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung CancerPuma Biotechnology, Inc. · Carcinoma, Non-Small-Cell LungCompletedPBYILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 34 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner